EU-approved Humira

BIOLOGICAL3 trials

Sponsors

Fresenius Kabi SwissBioSim GmbH, Celltrion

Conditions

HealthyHealthy SubjectsModerate to Severe Chronic Plaque Psoriasis

Phase 1

MSB11022 in Healthy Subjects

CompletedNCT03014947

Fresenius Kabi SwissBioSim GmbHHealthy Subjects

Start: 2014-05-31End: 2014-12-31Updated: 2019-07-01

To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects

CompletedNCT03970824

CelltrionHealthy

Start: 2019-05-31End: 2020-01-15Updated: 2021-11-18

Phase 3

To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis

CompletedNCT05495568

CelltrionModerate to Severe Chronic Plaque Psoriasis

Start: 2022-11-07End: 2024-02-05Updated: 2024-08-21

Related Papers

CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study

Dermatology and Therapy2025-03-27

Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.

2025-02-113 citations

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.

2021-02-0520 citations

Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects

Clinical and Translational Science2021-01-2716 citations

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.

2020-12-0134 citations